TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05694221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered subcutaneously in the Supaglutide arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Administered subcutaneously in the Supaglutide arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral Administration
Study: NCT04845529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
Study: NCT04785690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis.
Study: NCT05112276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
Study: NCT05545280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine with glycopyrrolate
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Administration by intravenous infusion
Study: NCT05307367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
Study: NCT05507788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wheelchair air cushion
Description: Reaching tasks during each of the seating conditions decribed in the Arms section.
Study: NCT06425627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: An intrathecal anesthetic technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: An intravenous (combined with inhalation) anesthetic technique.
Study: NCT04745260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl Spray and Intranasal Midazolam Spray
Description: Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Midazolam Spray
Description: Intranasal Midazolam 0.3mg/kg
Study: NCT04694586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: rifampicin 35 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 40 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRZE
Description: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR
Description: isoniazid 75 mg + rifampicin 150 mg combination tablets
Study: NCT04817917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine (Vero Cell), Inactivated;
Description: The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine (Vero Cell), Inactivated;
Description: The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
Study: NCT05759052

Intervention type: BEHAVIORAL
Intervention: self-administered questionnaire
Description: Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
Study: NCT05402384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-801
Description: Medical grade D-galactose~dosage:2.0 g/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AVTX-801
Description: Medical grade D-galactose~dosage:2.0 g/kg/day
Study: NCT04817917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No prospective interventions
Description: The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No prospective interventions
Description: The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No prospective interventions
Description: The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
Study: NCT04898894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given in to the vein (IV) or intrathecal (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneous (SubQ, SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecal (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate/hydrocortisone/cytarabine
Description: Given intrathecal (IT)
Study: NCT06545396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half-dose illumination protocol
Description: Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-dose illumination protocol
Description: Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
Study: NCT05853874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (dietary protocol)
Description: The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital standard of care
Description: The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
Study: NCT05402384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06334367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 treatment
Description: CD25 prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ATG
Description: HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.

Intervention type: DRUG
Group type: OTHER
Intervention: low-dose ATG
Description: HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
Study: NCT05863715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Search Cue Type
Description: Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
Study: NCT05789992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (Random:3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (Random:3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (Random:3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (Random:3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Remifentanil
Description: Remifentanil (Random:0-3ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Remifentanil
Description: Remifentanil (Random:0-3ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heigh Remifentanil
Description: Remifentanil (Random:3-5ug/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heigh Remifentanil
Description: Remifentanil (Random:3-5ug/ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Endotracheal intubation before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Endotracheal intubation before surgery
Study: NCT05926375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HINEX Jelly ( jelly high protein supplement)
Description: In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HINEX Jelly ( jelly high protein supplement)
Description: In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
Study: NCT05806489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
Study: NCT05789992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tetanic electrical stimulation
Description: tetanic electrical stimulation before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tetanic electrical stimulation
Description: tetanic electrical stimulation before surgery
Study: NCT05532423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot Juice - Active
Description: Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beetroot juice - Placebo
Description: Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
Study: NCT05265780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesiotape
Description: an elastic adhesive tape

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham taping
Description: a sham taping without the tension
Study: NCT05264220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Matrix
Description: Participants will receive a 4 session psychological intervention based on the ACT Matrix
Study: NCT06163677

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receipt of Pfizer BioNTech COVID-19 vaccine
Study: NCT05023369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)
Description: Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
Study: NCT04894461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
Study: NCT06138223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
Study: NCT05581901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose1)
Description: Dose: 0.10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose 2)
Description: Dose: 0.15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose 3)
Description: Dose 0.20mg/kg
Study: NCT05555173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy is a small vibrating bee with ice-pack wings.
Study: NCT05015413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shock wave master 500 Germany

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shock wave master 500 Germany
Study: NCT04987944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: 150 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active drug
Study: NCT05421884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Love Languages
Description: Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
Study: NCT05277480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+IE
Description: apatinib po； ifosfamide ivgtt ; etoposide ivgtt .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IE
Description: ifosfamide ivgtt ; etoposide ivgtt .
Study: NCT05207189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UVT
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
Study: NCT04801407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous radiofrequency trigeminal rhizotomy
Description: percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular decompression of the trigeminal nerve
Description: Microvascular decompression is a procedure that decompress the nerve from vascular conflict
Study: NCT05760716

Intervention type: OTHER
Intervention: practicing prone position
Description: Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
Study: NCT04572009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mathematical model
Description: bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without bio-mathematical model
Description: No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
Study: NCT05700643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency cherry supplement
Description: Montmorency cherry supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT05015985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music-Care
Description: music relaxation by a specific hardware and software program application (MUSIC-CARE)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: music relaxation using a music playlist supply (control group)